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Despite the enormous scientific progress in the field of
regenerative medicine, there are no cells that provide a cure
for everything and everyone. Stem cells have raised tremen-
dous expectations among the medical doctors, researchers,
patients, and the general public due to their capacity to differ-
entiate into a broad range of cell types. Stem cell researchers
are engaged in different endeavors, including treating genetic
disorders and generating new stem cell-derived human
tissues and biomaterials for use in pharmacy, genomics,
and regenerative medicine. Results obtained from completed
and on-going clinical studies during the last decades demon-
strate rapid progress and the increased importance of stem
cells in both basic research and the long-term future of
modern medicine indicating the huge therapeutic potential
of stem cells in the treatment of degenerative, autoimmune,
and genetic disorders.
Mesenchymal stem cells (MSCs) are considered as new
therapeutic agents in the treatment of immune-mediated
diseases, particularly due to their immunomodulatory charac-
teristics. In cell-to-cell contact and through the production of
solublemediators,MSCs can regulate the proliferation, activa-
tion, and effector function of T lymphocytes, professional
antigen presenting cells, NK cells, NKT cells, and neutrophils.
MSCs suppress inflammatory (M1) macrophages and
promote their conversion in alternative (M2) phenotype in
prostaglandin E2 (PGE2), tumor necrosis factor alpha-
(TNF-α-) stimulated gene/protein 6 (TSG-6), interleukin-
(IL-) 6, and indoleamine 2,3-dioxygenase- (IDO-) dependent
manner. In line with these findings, in their article published
in this special issue, S. Ravanidis and coworkers described
molecular mechanisms involved in interplay between mac-
rophages and multipotent adult progenitor cells (MAPC), a
stem cell population sharing common mesodermal origin
with MSCs. S. Ravanidis et al. showed that MAPC, in a
cyclooxygenase 2- (COX-2-) dependent manner, suppressed
the secretion of TNF-α in M1 inflammatory macrophages
while, at the same time, inflammatory macrophages trig-
gered the immunomodulatory properties ofMAPC, including
an increased expression of immunomodulatory mediators
(inducible nitric oxide synthase (iNOS) and COX-2), che-
mokines, and chemokine receptors. Moreover, S. Ravanidis
and colleagues showed that the MAPC secretome sup-
pressed the antigen-specific proliferation of autoreactive T
cells and attenuated their capacity to activate inflammatory
macrophages. Data published in this article revealed mecha-
nisms involved in the interactions between MAPC and
inflammatory macrophages, which could be important for
the design of new MAPC-based therapeutic strategies for
the treatment of inflammatory disorders in which myeloid
cells play a crucial role.
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MSCs are adult stem cells that can be isolated from
various numbers of postnatal tissues. Bone marrow (BM)
has been the main source for the isolation of multipotent
MSCs. BM-MSCs have many properties that enable their
therapeutic use: easy acquisition, quick proliferation in vitro,
low surface expression of major histocompatibility complex
(MHC) antigens and minor immunological rejection,
long-term coexistence in the host, maintenance of differen-
tiation potential after repeated passages, and ease of trans-
plantation. Since the derivation of BM-MSCs involves
harvesting of BM that is a highly invasive procedure, alterna-
tive sources have been strongly pursued. In this special issue,
immunomodulatory characteristics of BM-MSC, synovial-
membrane-derived MSCs (SM-MSCs), human placenta-
derived MSCs (hP-MSCs), and adipose tissue-derived MSCs
(AT-MSCs) were described and their therapeutic potential
was investigated in well-established animal models of acute
renal injury, arthritis, and liver fibrosis.
Since AT-MSCs can be easily isolated from liposuctions,
AT represents an important source of MSCs. Accordingly,
Y. Wu and coworkers investigated cytokine secretion profile
of AT-MSCs in order to further emphasize their potential in
cellular immunotherapy. As it was described by Y. Wu et al.,
AT-MSC cultures were heterogeneous in phenotype indicat-
ing that all AT-MSCs did not contribute to the immune-
suppression in the same manner. Although all AT-MSCs
were capable to produce IL-6, only 10–20% of AT-MSCs
expressed IL-6 receptor (CD130) on their surface. Similarly,
IFN-γ was produced by only 1.4% of AT-MSCs, but
18–31% of AT-MSCs expressed receptor of IFN-γ (CD119)
indicating that AT-MSCs did not produce inflammatory
cytokines but had the capacity to respond on them. Results
obtained by Y. Wu and colleagues demonstrate that
AT-MSCs are heterogeneous in their cytokine secretion
and receptor expression profiles which are an important
information for their future therapeutic use.
AT-MSCs were also in the focus of the research
conducted by I. Muñoz-Criado et al. who investigated regen-
erative potential of AT-MSCs in the animal model of severe
osteoarthritis (OA). They showed that transplantation of
suprapatellar-derived AT-MSCs significantly diminished
the OA-associated knee inflammation and cartilage degener-
ative grade by increasing the production of glycosaminogly-
can and by inducing endogenous chondrogenesis. Results
obtained by I. Muñoz-Criado and colleagues strongly
suggest transplantation of autologous suprapatellar-derived
AT-MSCs as a new therapeutic approach for patients with
multiple degenerative OA.
Advanced liver fibrosis results in cirrhosis, liver failure,
and portal hypertension and often requires liver transplanta-
tion. However, liver transplantation has several limitations,
including lack of donors, complications of surgical interven-
tions, side effects of immuno-suppressive drugs, and high
medical costs. Accordingly, the alternative approaches such
as stem cell transplantation have been suggested as an
effective alternate therapy to liver transplantation. In line
with these findings, J. Yu and coworkers showed that
transplantation of hP-MSCs efficiently repaired carbon
tetrachloride- (CCl4-) induced liver fibrosis in rats, as
evaluated by enhanced liver function tests, improved histo-
pathology, reduced Sirius red-stained collagen area, and
downregulated expression of fibrotic markers: transforming
growth factor beta (TGF-β) and alpha smooth muscle actin
(α-SMA). Moreover, by using green fluorescent protein,
J. Yu et al. demonstrated that transplanted hP-MSCs
successfully engrafted in the injured livers where it were
able to restore liver function, suggesting their therapeutic
potential in the treatment of liver fibrosis.
In many cisplatin-treated patients, kidney injury is irre-
versible, requiring substitution, reduction, or discontinuation
of cisplatin treatment. Since currently there is no compatible
and convenient chemotherapeutic agent with similar potent,
anticancer efficacy as cisplatin, clinical use of cisplatin cannot
be abandoned. Accordingly, an urgent demand exists for
researchers to develop new adjuvant therapy for attenuation
of cisplatin-induced nephrotoxicity and inflammation. B. S.
Markovic and coworkers demonstrated that BM-MSCs can
attenuate cisplatin-induced acute renal failure by suppressing
migration and activation of immune cells in inducible nitric
oxide synthase- (iNOS-) dependent manner. They noticed
significantly decreased levels of inflammatory cytokines
TNF-α and IL-17 and increased levels of anti-inflammatory
cytokines IL-10, IL-6, nitric oxide (NO), and kynurenine in
sera of cisplatin-treated mice that received BM-MSCs or
MSC-conditioned medium (MSC-CM) indicating that MSCs
exert their beneficial effects in paracrine manner. Moreover,
BM-MSC or MSC-CM treatment significantly attenuated
influx of immune cells: macrophages, dendritic cells, neutro-
phils, and T lymphocytes in damaged kidneys and attenuated
their capacity to produce TNF-α and IL-17. Importantly,
inhibition of iNOS completely diminished renoprotective
and immuno-suppressive effects of MSC-CM. Results
obtained by B. S. Markovic and colleagues provide the
evidence that BM-MSCs, in paracrine, iNOS-dependent
manner, attenuate inflammation in cisplatin-induced neph-
rotoxicity. These findings could be helpful in developing
new BM-MSC-based therapeutic approaches for attenuation
of cisplatin-induced nephrotoxicity.
Rheumatoid arthritis is an autoimmune, systemic inflam-
matory disease characterized by persistent inflammation,
extensive synovial hyperplasia, and cartilage and bone
destruction that is developed as a consequence of enhanced
Th1 and Th17 immune response and suppressed activity of
T regulatory and B regulatory cells. MSCs have the potential
to suppress both Th1- and Th17-driven inflammation and to
promote expansion of regulatory cells in peripheral lymph
organs. Accordingly, in this special issue, M. Yan and
coworkers demonstrated that intra-articular injection of
SM-MSCs ameliorated clinical and histological severity of
collagen-induced arthritis by decreasing production of Th1
and Th17 inflammatory cytokines (TNF-α, IFN-γ, and
IL-17A) and by increasing production of anti-inflammatory
and immuno-suppressive IL-10. Moreover, cellular makeup
of the spleens revealed decreased number of Th1 and Th17
cells and increased presence of Th2 lymphocytes, PD-1+
CXCR5+FoxP3+ follicular T regulatory cells, and CD19+
CD5+CD1d+IL-10+ regulatory B cells in mice that received
SM-MSCs. Data obtained by M. Yan and colleagues
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demonstrated therapeutic potential of SM-MSCs for the
suppression of immune response and inflammation during
the progression and development of rheumatoid arthritis.
Although immuno-suppressive characteristics of MSCs
are beneficial in the treatment of inflammatory and autoim-
mune diseases, they can represent a serious problem if
patient that received MSCs has primary or metastatic tumor.
By using mice model of metastatic lung cancer, M. Gazdic
and coworkers showed that intravenous application of
BM-MSCs significantly suppressed systemic antitumor
immune response, reduced total number of lung-infiltrated
dendritic cells, macrophages, and CD4+ T lymphocytes,
and attenuated antitumor cytotoxicity of cytotoxic T lym-
phocytes and NK cells resulting with the expansion of
metastatic lesions in the lungs. This phenomenon was
abrogated by inhibitors of iNOS and IDO, suggesting
importance of iNOS and IDO for MSC-mediated sup-
pression of antitumor immune response. Data obtained by
M. Gazdic and colleagues raise serious concerns regarding
safety of MSC-based therapy in patients who have genetic
susceptibility for malignant diseases.
In summing up, articles in this special issue present novel
findings regarding molecular and cellular mechanisms
involved in MSC-based suppression of immune response in
inflammatory and malignant diseases underlining the impor-
tance of preclinical studies in the development of efficient
and low-cost regenerative medicine.
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